Gutwerg Ori 4

What Happened Ori Gutwerg, Senior Vice President, Generics at ANI Pharmaceuticals, had a total of 3,663 shares withheld/disposed to satisfy tax obligations tied to restricted stock vesting. On Feb 12, 2026, 1,775 shares were withheld at $76.70 per share (value $136,143). On Feb 14, 2026, 1,888 shares were withheld at $77.36 per share (value $146,056). Combined value of the withheld shares is about $282,199. These transactions are coded as F (shares withheld for tax purposes), not open-market sales.

Key Details

• Transaction dates & prices: Feb 12, 2026 — 1,775 shares @ $76.70 ($136,143); Feb 14, 2026 — 1,888 shares @ $77.36 ($146,056).
• Total shares withheld/disposed: 3,663; total value ≈ $282,199.
• Shares owned after the transaction: Not stated in this filing.
• Footnotes:
  • F1: Withheld in connection with vesting of 3,917 restricted shares (grant reported Feb 18, 2025).
  • F2: Withheld in connection with vesting of 3,691 restricted shares (grant reported Feb 16, 2024).
  • Transactions are exempt under Rule 16(b)-3 as tax-withholding related.
• Filing timeliness: Form 4 filed Feb 17, 2026 for transactions on Feb 12 and Feb 14 — Form 4s are normally due within 2 business days, so this filing appears later than typical.

Context Code F indicates a sell-to-cover / shares‑withheld event to satisfy tax withholding upon restricted stock vesting. These are routine, administratively driven dispositions and do not necessarily indicate the insider’s view of the company’s prospects. The footnotes reference the original restricted-stock grant dates tied to the vesting events.